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ABSTRACT
Prostate cancer (PCa) is the most common cancer among men in developed 
countries. Although its genetic background is thoroughly investigated, rather little 
is known about the role of small non-coding RNAs (sncRNA) in this disease. tRNA-
derived fragments (tRFs) represent a new class of sncRNAs, which are present in 
a broad range of species and have been reported to play a role in several cellular 
processes. Here, we analyzed the expression of tRFs in fresh frozen patient samples 
derived from normal adjacent prostate and different stages of PCa by RNA-sequencing. 
We identified 598 unique tRFs, many of which are deregulated in cancer samples when 
compared to normal adjacent tissue. Most of the identified tRFs are derived from the 
5’- and 3’-ends of mature cytosolic tRNAs, but we also found tRFs produced from 
other parts of tRNAs, including pre-tRNA trailers and leaders, as well as tRFs from 
mitochondrial tRNAs. The 5’-derived tRFs comprise the most abundant class of tRFs in 
general and represent the major class among upregulated tRFs. The 3’-derived tRFs 
types are dominant among downregulated tRFs in PCa. We validated the expression 
of three tRFs using qPCR. The ratio of tRFs derived from tRNALysCTT and tRNAPheGAA 
emerged as a good indicator of progression-free survival and a candidate prognostic 
marker. This study provides a systematic catalogue of tRFs and their dysregulation 
in PCa and can serve as the basis for further research on the biomarker potential and 
functional roles of tRFs in this disease.
INTRODUCTION
Prostate cancer (PCa) is the second most 
common cancer in men worldwide [1]. The treatment 
of PCa is hampered by the lack of reliable markers for 
disease outcome prediction leading to incorrect patient 
stratification, overtreatment and consequent side effects 
from prostatectomy and radiation therapy [2]. A better 
understanding of the molecular mechanisms behind 
the onset and progression of PCa is needed in order to 
discover better markers and develop new therapeutic 
strategies. The role of small non-coding RNAs (sncRNAs) 
other than microRNAs (miRNAs) in PCa is poorly 
understood. The rapid progress and popularity of high 
throughput sequencing led to the discovery of a novel 
class of sncRNAs derived from tRNAs and named tRNA-
derived fragments (tRFs) [3–5]. tRFs are present across all 
domains of life [6–8]. While initially considered random 
products of tRNA turnover, their abundance and ubiquitous 
expression suggest that tRFs are actual biological entities 
[6, 7].
tRFs can be generated by endonucleases such as 
ribonuclease T2 (Rny1p) in yeast and angiogenin or dicer 1 
in human. Based on size, they are divided into two groups. 
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The first group consists of tRFs with a size of 30 to 35 nt, 
which are generally referred to as tRNA halves or stress-
induced tRFs. tRNA halves are produced by endonucleolytic 
cleavage at the anticodon loop of the full-length tRNA. The 
second group consists of tRFs with a size of about 20 nt 
and can be further divided into 5’- and 3’-derived tRFs, 
originating from the 5′- and 3′-parts of mature tRNAs, 
respectively [4, 9, 10]. The small RNAs derived from the 
5’-leader and 3’-trailer sequences of the precursor tRNAs 
(pre-tRNAs) are also classified as tRFs [5, 11, 12].
Expression of tRFs is detected in different cancer 
cell lines, including the PCa cell lines LNCaP and C4-2 [4, 
5, 13–15]. In a previous study, we reported the discovery 
and differential expression of tRFs in clinical samples of 
PCa [16]. This suggests that tRFs might play an important 
role in the pathogenesis of cancer. The mechanism behind 
the function of tRFs appears to be diverse. Several reports 
demonstrate that tRF levels are elevated by cellular 
stress conditions and particularly under oxidative stress 
such as hypoxia [10, 13, 15, 17]. tRFs are also involved 
in post-transcriptional regulation of gene expression via 
direct inhibition of protein synthesis by displacing the 
eIF4G translation initiation factor from mRNA [18–20]. 
Moreover, a 3′-derived tRF identified in B-cell lymphoma 
cells possesses the functional characteristics of a guide 
RNA that suppresses proliferation and modulates response 
to DNA damage in a miRNA-fashion [21]. It has also 
been shown that tRFs can compete for the binding sites 
of the RNA-binding protein YBX1, which is involved in 
the stabilization of oncogenic transcripts suppressing cell 
growth and invasion [15]. In this way, tRFs antagonize 
the activity of YBX1 and act as tumor suppressors. Taken 
together, these findings strongly suggest a functional role 
of tRFs in tumorigenesis.
Very recently, it was proposed that although tRFs 
are defined biological entities, their composition and 
abundance in the transcriptome is dependent on gender, 
tissue, disease and even disease subtype [22]. This 
suggests that tRFs can be explored as novel sensitive 
biomarkers of disease. Yet, studies providing systematic 
insight into the composition and expression of the tRF 
transcriptome throughout various disease stages are still 
missing. Here, we analyze tRF expression in an extended 
cohort of clinical samples representing progressing stages 
of PCa. We construct a database of tRFs expressed across 
PCa samples and identify the most differentially expressed 
tRFs. Finally, we perform a qPCR quantification in two 
cohorts of clinical samples to validate the differential 
expression of selected tRFs.
RESULTS
Inventory of tRFs expressed in PCa
In order to obtain a global overview of the tRF 
repertoire in PCa, we analyzed tRFs across normal 
adjacent prostate (NAP), benign-prostate hyperplasia 
(BPH), PCa from radical prostatectomies, trans-urethral 
resected tissue from castration resistant PCa (TURP_
PCa), and lymph node metastasis (LN_PCa) using next-
generation RNA sequencing (Table 1).
All 21 cytosolic tRNA isotypes (including 
selenocystein tRNAs) were found to produce tRFs in 
variable amounts (Figure 1A). tRNAAla and tRNALys 
showed the highest numbers of mapped tRFs, while the 
least tRFs were produced from tRNAIle and tRNAAsp. The 
raw sum of tRFs weakly correlated with the number of 
tRNA genes per isotype or anticodon, as well as with 
the percentage of codon usage (Supplementary Figure 
1; codon usage from http://gtrnadb.ucsc.edu/Hsapi19/
Hsapi19-summary-codon.html). tRFs derived from 15 out 
of 20 mitochondrial tRNAs (mtRNAs) were also detected 
(Figure 1A). We could not detect tRFs corresponding to 
the mitochondrial tRNA isotypes mtRNAGln, mtRNAGlu, 
mtRNALys, mtRNATrp and mtRNAVal. With the exception 
of mtRNAPhe, most mtRNA isotypes had a lower number 
of mapped tRFs, compared to cytosolic tRNAs. The read 
count of mtRNAPhe in the NAP group was 83-fold higher 
than the average of all other mtRNA read counts.
In order to quantify the expression of tRFs, we 
assembled a PCa tRF-database using the fragment 
detection algorithm FlaiMapper [23]. The read-coverage of 
mature cytoplasmic tRNAs across all groups was analyzed 
using CLC-Bio Genomics Workbench. Initially, 1175 
tRFs were identified and mapped to 386 unique cytosolic 
tRNAs [24]. However, since tRNA sequences are highly 
conserved within tRNA isotypes, some tRFs were mapped 
to more than one unique tRNA (Supplementary Figure 2) 
and the total read-count in the initial mapping was equally 
divided across them. Upon further examination, we 
noticed that this causes underrepresentation of sequence 
counts for tRFs that had identical sequence but could 
be mapped to multiple tRNA isotypes. Therefore, tRFs 
with identical sequences were merged into single entries, 
even if they could be derived from different tRNAs, 
and their corresponding reads were summed. After this 
correction, a total of 598 unique tRFs were identified 
(Supplementary Table 1). Multiple fragmentation patterns, 
in combination with low read-count, caused low reliability 
in the automated prediction of tRFs derived from mtRNAs 
(Supplementary Figure 3). Therefore, these tRFs were 
omitted from further analysis.
Based on their size, tRNA-derived fragments can 
be generally separated into two major categories: tRNA 
halves, with a size of 30-35 nt and small tRNA fragments 
(tRFs), with a size of approximately 20 nt. In our dataset, 
small tRFs were predominant and their sizes ranged 
from 15 to 23 nt (Figure 1B). The most abundant tRFs, 
however, were between 18 to 21 nt, while 40% of tRFs 
were 19 nt long (Figure 1B). A group of longer tRFs, with 
sizes between 25 and 29 nt, was also identified.
In addition to tRFs derived from mature tRNAs, we 
were also able to detect fragments corresponding to the 
5’-pre-tRNA leader (5’U-tRFs) and 3’-pre-tRNA trailer 
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(3’U-tRFs) sequences of various tRNAs (Supplementary 
Table 2). The length of 5’U-tRFs and 3’U-tRFs varied 
between 15 and 25 nt. Most 5’U-tRFs were 17 nt long and 
most 3’U-tRFs were 18 nt long (Supplementary Figure 
4A). Interestingly, more than 54% of 3’U-tRFs and 30% of 
5’U-tRFs were derived from sequences right next to or 1 
nt away from the mature tRNA sequence (Supplementary 
Figure 4B-4C), suggesting that they are produced during 
the normal processing of pre-tRNA. Both 5’U-tRFs and 
3’U-tRFs showed overall low expression values (data 
not shown), with the exception of tRF-1001/cand45. This 
fragment was previously detected in PCa cell lines, as 
well as in human colon carcinoma and human embryonic 
kidney cells [5, 11]. In our libraries tRF-1001/cand45 
showed read counts from 40 000 in the NAP and PCa 
(average) groups to 110 000 in the LN_PCa group.
tRFs derived from the 5’-end are dominant in PCa
The majority of tRFs identified in our samples 
originate from the 5′- and the 3′-end of tRNAs (Figure 1C). 
This is in concordance with previous studies collectively 
reporting on the existence of short tRFs derived from the 
5′- and the 3′-end of mature tRNAs [5, 25, 26]. To analyze 
the relative abundance of each tRF class in our dataset we 
examined the start and end positions of all unique tRFs 
on their precursor tRNAs. All the fragments with a 3’-end 
nucleotide at position ≤40 on the mature tRNA sequence 
were considered as 5′-derived, whereas all fragments with 
the first 5’-nucleotide at position ≥30 on the mature tRNA 
sequence were considered as 3′-derived. Based on fragment 
uniqueness, we found comparable rates of tRF types, i.e. 
51.7% corresponded to 5′-derived tRFs and 44.2% to 
3′-derived tRFs. Nevertheless, when relative fragment 
abundance was taken into account a strong bias towards the 
5′-derived (84.7%) vs. the 3’-derived tRFs was observed.
To get a more precise overview of the localization 
of tRFs, we also analyzed their start- and end- position 
frequencies. Interestingly, more than 26% of all unique 
tRFs, which in the terms of abundance account for over 
80% of all tRFs, were found to start at position 1 on the 
mature tRNA sequence (Figure 1D–1E). Most of these 
Table 1: Clinical parameters of the samples used for the RNA-sequencing
Group 
name
Patient 
samples
TMPRSS2_
ERG fusion
ETV1 
aberrations
Cancer 
cells (%)
Gleason 
score
Preoperative 
PSA Mean 
(Min.- 
Max.)
Status after 
radical 
prostatectomy*
NAP 4 0 (0%) 0 0 N/A 5.8 (2.5 - 11) N/A
BPH 4 N/A N/A 0 N/A N/A N/A
PCa6_cur 4 4 (100%) 0 70-90 3+3 3.8 (2.0 - 
7.2)
Cured
PCa6_
nofusion 4 0 (0%) 0 70-90 3+3
10.8 (0.5 - 
23.7)
Recurrent
PCa6_
TERG 4 4 (100%) 0 80-90 3+3
7.3 (2.0 - 
10.5)
Recurrent
PCa6_recur 4 4 (100%) 0 80-90 3+3 11.3 (6.0 - 
64.3)
Recurrent
PCa7_recur 4 2 (50%) 1 (fusion) 80-100 4+3 25.2 (6.5 - 
64.3)
Recurrent
PCa8_recur 3 1 (25%) 1 
(overexpressed)
90-100 4+4 (5)
32.4 (31.9 - 
32.9)
Recurrent
TURP_PCa 
(castration 
resistant)
4 1 (25%) 1 (fusion) 90-100 (3+4) to 
(5+4)
Unknown Recurrent
LN_PCa 4 3 (75%) 1 (fusion) 100 4+4(5)† 154.6 (80.2 - 
252.5)
N/A
* Patients were considered cured if there was no biochemical relapse or detection of metastasis after radical prostatectomy
† Gleason score of the primary tumor
Group abbreviations: NAP, normal adjacent prostate; BPH, benign prostatic hyperplasia; PCa, organ-confined prostate 
cancer; cur/recur, cured/recurrent after radical prostatectomy; PCa6_nofusion, PCa Gleason score 3+3 with no TMPRSS2- 
ERG fusion or ETV abnormalities; PCa6_TERG, PCa Gleason score 3+3 with TMPRSS2-ERG fusion; TURP_PCa, trans-
urethral resection of the prostate, castration resistant PCa; LN_PCa,   lymph node metastasis.
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tRFs have the end at position 19 on the mature tRNA. 
Based on the peaks generated by the start positions of all 
unique fragments (Figure 1D), we observed that the tRF 
pool constitutes of several distinct classes (note the peak 
appearing before 20 nt, another at around 40 nt and another 
before 60 nt of the mature tRNA). While categorizing tRFs 
into 5′- or 3′-derived tRFs is very common, we found that 
at least 5 different classes are present across our samples. 
Therefore, we classified tRFs into (i) 5e-tRFs with a start 
position in the first nucleotide of the 5’-end of the tRNA 
(“e” stands for “end”); (ii) D-tRFs with a start position 
between nucleotides 12-23 and overlapping the D-loop 
of the precursor-tRNA; (iii) A-tRFs starting between 
nucleotides 31-39 and overlapping with the anticodon 
loop; (iv) V-tRFs with a start between nucleotides 45-49 
and overlapping the variable loop; and finally, (v) 3e-tRFs 
starting between nucleotides 50-60 and overlapping the 
T loop (Figure 1F). While 5e-tRFs represent the most 
abundant class of tRFs (approximately 75%), other 
classes of tRFs appear to have very similar expression 
(<10% abundance) compared to each other (Figure 1G). 
Interestingly, similar tRF types have been detected in the 
Figure 1: tRF types in prostate cancer. A. Heatmap showing the total read counts mapped to individual tRNA isotypes in three study 
groups: NAP, normal adjacent prostate; PCa, prostate cancer group (consisting of 6 different sample pools, the average value is shown); 
LN_PCa, lymph node metastasis. The color and its corresponding value in log
10
 scale are depicted on the right. B. tRF length as based 
on the read abundance (orange bars) and uniqueness (dotted line). C. Graph depicting the locations of mapped tRFs on the sequences 
of mature tRNAs. Full-length tRNA sequences are aligned to the middle using the anticodon position. tRFs mapped to these tRNAs are 
depicted as grey bars which relative abundance per particular tRNA is reflected by the color intensity (light grey, low abundance; black, 
high abundance). tRNAs with only one mapped tRF are clustered at the top, tRNAs with two mapped tRFs in the middle and tRNAs with 
multiple mapped tRFs are at the bottom. D-E. Start (blue line) and end (orange line) positions of tRFs on the mature tRNA sequence. 
Relative abundance of each tRF start and end based on the uniqueness (D) or abundance (E) is shown. F. An illustration of various tRF 
types and their approximate location on the secondary structure of tRNA. G. Relative proportions of each tRF types in our dataset as based 
on the uniqueness (% of unique independent reads) or abundance (% of total number of reads).
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lower eukaryote Tetrahymena thermophile, suggesting the 
existence of an evolutionary conserved tRNA processing 
mechanisms [27]. Moreover, the position of these peaks 
was found to overlap with all tRNA loops, indicating that 
endonucleolytic cleavage occurs in the single-stranded 
loop regions of tRNAs.
Several tRFs are deregulated in PCa
To investigate whether tRF production is 
dysregulated in PCa, we compared the expression levels 
of tRFs in normal tissue and in samples from different 
clinical stages representing progressing disease (Table 
1). While expression levels of other types of sncRNAs 
correlated well between the two libraries representing 
non-malignant tissue, i.e. NAP and BPH (Pearson r=0.89, 
P-value <0.0001; median fold-change -0.002), tRFs 
showed lower correlation and a very high one-directional 
deviation towards increased expression in the BPH library 
(Pearson r=0.81; P-value <0.0001; median fold-change 
0.758; Supplementary Figure 5). These results indicate that 
tRFs, as opposed to other sncRNAs, might be differentially 
expressed in benign prostate hyperplasia. This difference 
can be explained by the different anatomical origin of 
the BPH and NAP/PCa samples. While BPH occurs 
exclusively in the transition zone of the prostate, prostate 
tumors are predominantly localized in the peripheral zone. 
Both zones are characterized by distinct expression profiles 
indicating differential regulation of a large number of 
genes [28]. For this reason, BPH was excluded as a control 
sample from further analyses. Only NAP tissue, confirmed 
to contain 0% tumor cells by two independent pathologists, 
was used as a control sample. It should be acknowledged, 
that adjacent tissue could be altered in gene/ncRNA 
expression due to tumor-stroma paracrine influences [29]. 
Nevertheless, as much as stroma/epithelium interactions 
are unavoidable in experiments were samples are derived 
by macro-dissection, much care has been taken to minimize 
the influence of the stromal compartment on the expression 
profiles of small RNAs by selecting tissue sections of at 
least 70% epithelial cells [24].
We found several tRFs to be significantly 
differentially expressed in PCa when compared to NAP 
(Kal’s Z-test with Bonferroni correction, p-value < 0.05) 
(Figure 2 and Supplementary Table 3-4). The number of 
differentially expressed tRFs varied slightly between 
the stages of PCa, with a minimum of 27 differentially 
expressed tRFs in PCa6_recur group and a maximum of 
61 differentially expressed tRFs in the LN_PCa group 
(Figure 2, Supplementary Table 4). We identified 12 tRFs 
to be commonly differentially expressed between recurrent 
PCa groups with Gleason grade 6, 7, or 8 (Supplementary 
Table 5). Of these, 5 were upregulated, 6 downregulated 
and 1 was downregulated in PCa6 group but upregulated in 
PCa7 and PCa8 groups (Supplementary Table 5). This result 
indicates that a small subset of differentially expressed tRFs 
can be found across increasing grades of PCa.
In summary, we found 110 differentially expressed 
tRFs across our dataset, out of which 72 were upregulated, 
24 downregulated and 13 that were upregulated in one but 
downregulated in other group.
tRFs deregulated in PCa belong to distinct 
classes
It has been proposed that 5′- but not 3′-derived 
tRFs, play a role in stress granule assembly or inhibition 
of protein synthesis in vitro [19, 30]. On the other hand, 
some 3′-derived tRFs are able to repress their mRNA 
targets in a miRNA-like fashion and may exert tumor 
suppressive functions [21, 31]. Interestingly, our results 
indicate that the deregulation of 5’-derived tRFs differs 
from that of 3’-derived tRFs (Figure 2). In order to study 
which tRF types are present among the downregulated 
and upregulated tRFs in PCa we compared the percentage 
of different tRF types among our groups of upregulated 
and downregulated tRFs (Figure 3A–3B). We noticed 
major differences in the abundance of tRF types in 
both lists. Most of the upregulated tRFs were 5e-tRFs 
(50%) and most downregulated were 3e-tRFs (50%). 
We selected tRFs originating from 6 different tRNAs for 
further analysis and qPCR validation. All of them were 
commonly differentially regulated in recurrent PCa groups 
with Gleason grade 6, 7, or 8 (Supplementary Table 5). 
Out of these, 4 tRFs (three 5e-tRFs and one D-tRF) were 
upregulated in PCa (Figure 3C–3F), and 2 tRFs (both from 
the 3e-tRF class) were downregulated (Figure 3G–3H).
Specific tRF signatures can serve as prognostic 
marker of recurrent prostate cancer
The expression levels of tRFs selected for validation 
by qPCR were studied in a cohort of clinical samples 
obtained from Erasmus MC, Rotterdam (cohort 1) and 
a cohort of samples from Tampere University Hospital, 
Tampere (cohort 2). The NAP samples were identical for 
both cohorts and were processed independently in cohort 
1 and cohort 2 to account for technical differences in 
sample treatment. Using custom designed primers, we 
could detect three tRFs (Figure 4A–4C). tRF-544 (derived 
from tRNAPheGAA) was significantly downregulated in the 
recurrent PCa compared to NAP or cured PCa in cohort 
1 (Figure 4A). In cohort 2, tRF-544 was downregulated 
in PCa with Gleason score higher than 7 or in PCa 
with pathological stage 3 suggesting association with 
aggressive or late stage disease. The differential 
expression of this tRF was also confirmed in a second deep 
sequencing analysis of a sub-set of PCa samples from 
Tampere University Hospital (unpublished data). tRF-315 
(derived from tRNALysCTT) was significantly upregulated 
in all PCa groups of cohort 2 (Figure 4B). We could not 
detect statistically significant difference in the expression 
of tRF-315 in the smaller cohort 1. Nevertheless, there was 
a clear trend of tRF-315 upregulation in the PCa samples. 
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tRF-562 (derived from tRNAGlyTCC) was significantly 
downregulated in PCa recurrent vs. NAP group in the 
cohort 1 and in the PCa pT3 vs. NAP group in the cohort 
2 (Figure 4C).
Interestingly, tRF-544 was consistently 
downregulated in samples from patients that developed 
recurrent disease compared to samples from patients 
that were cured by radical prostatectomy in both cohorts. 
Furthermore, tRF-544 expression was lower in high- 
(Gleason score ≥7) compared to low-grade (Gleason score 
<7) tumors (Figure 4A). Vice versa, tRF-315 demonstrated 
a clear trend of upregulation in recurrent disease and its 
expression was higher in high-grade tumors (Figure 4B). 
Therefore, we reasoned that the expression of these two 
tRFs might be prognostic for aggressive tumor growth 
and disease recurrence after radical prostatectomy. We 
took advantage of the opposing expression patterns of 
these two tRFs and calculated the expression ratio tRF-
315/tRF-544 for both cohorts (Figure 4D). The tRF-315/
tRF-544 ratio showed significant differences, clearly 
distinguishing high from low grade PCa and cured from 
recurrent disease. Moreover, high expression ratio was 
significantly associated with poorer progression-free 
survival and shorter period to disease relapse (Figure 4E), 
suggesting that the tRF-315/tRF-544 ratio might represent 
a helpful clinical biomarker of disease progression.
Figure 2: Differentially expressed tRFs in prostate cancer. Plotted are normalized read-count values of each tRF in the normal 
adjacent prostate versus various stages of prostate cancer. The baseline value for tRFs that are not expressed is 1. Full lines represent 4-fold 
change borderlines. Colored points represent significantly changed tRFs (Kal’s Z-test on proportions, Bonferroni corrected p-values, p < 
0.05) labeled as 5’-derived (magenta) and 3’-derived (green) tRFs. tRFs with the 3’-nucleotide at a position ≤40 on the precursor tRNA 
sequence are considered as 5′-derived. tRFs with the start nucleotide at a position ≥30 on the precursor tRNA sequence are considered 
as 3′-derived. tRFs that do not fall into either of these two categories are shown in blue. Positions of tRF-310, tRF-315, and tRF-389 
are indicated as an example of three differentially expressed tRFs. The graph at the bottom right corner summarizes the total number of 
differentially expressed tRFs per group. The amount of tRFs with ≥4-fold differential expression are indicated in dark orange (upregulated) 
or dark blue (downregulated) color.
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DISCUSSION
The technical progress in sequencing technologies 
and the rapid increase in the number of studies on 
sncRNA led to the discoveries of novel small RNA classes 
including tRFs. Since their initial identification, tRFs have 
been described in a plethora of species and knowledge 
about their function in the cell is starting to accumulate. 
Although several studies describe expression of tRFs in 
human cell lines, their actual repertoire in human tissues 
remains largely unknown [5, 15, 16, 22].
Here, we studied the composition and expression 
of tRFs in clinical PCa samples representing progressing 
disease stages. We found that all cytosolic tRNAs 
produced tRFs in the size range of 18-21 nt, representing 
the small class of tRFs. The longer tRNA halves were not 
as common, which is a consequence of the size selection 
(~15-35 nt) applied for the isolation of sncRNAs fraction 
in our study. We found a significant but weak correlation 
between the expression of tRFs per tRNA and the codon 
usage of tRNAs, suggesting that although tRF expression 
is dependent on the expression levels of their precursors, 
most likely additional mechanisms control tRF levels in 
the cell.
The accurate quantification of fragments derived 
from small RNAs in RNA sequencing data requires a 
precise annotation of the exact position of the fragment 
on its precursor transcript. To predict the locations of 
tRFs and quantify their expression we used the programs 
FlaiMapper and CLC-Bio Genomics Workbench [23]. We 
Figure 3: Frequency of tRF types among differentially expressed tRFs. A-B. Start (blue line) and end (orange line) positions 
of tRFs on the mature tRNA sequence and the proportions of each tRF type for 72 upregulated (A) and 24 downregulated (B) tRFs. C-H. 
Graphs showing the exact positions of 6 selected tRFs (shown in color) and other tRFs (shown in grey) on their tRNA precursors. The 
x-axis represents the position on the precursor sequence in nucleotides. The y-axis represents summed read-counts per sample group. The 
expression level per group is indicated by different color (see the legend at the bottom). Expression levels of other tRFs are shown as means 
across PCa groups.
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identified 598 unique tRFs derived from mature tRNAs. 
Based on the part of mature tRNA from which fragments 
originate, we could distinguish 5 different tRF classes. 
Out of these, the 5e-tRFs class was the most abundant 
of all and contained the highest number of unique tRFs. 
This finding is in agreement with other reports showing 
higher abundance of 5’-end derived tRFs [4, 5, 22, 32–
34]. Given the role of 5’-derived tRFs in the inhibition 
of proteosynthesis and their role in the assembly of stress 
granules, a type of stress-induced cytoplasmatic foci with 
high concentration of untranslated mRNPs [10, 19, 30], 
it would be interesting to test their potential to inhibit 
translation and induce the assembly of stress granules 
in vitro in PCa cell lines using the set of upregulated 
5’-derived tRFs identified in our study. The importance 
of tRFs in stress granule assembly becomes even more 
intriguing thanks to the latest indications that stress 
granules might play an important role in cancer via 
the negative regulation of mTORC1-hyperactivation-
induced apoptosis [35]. This suggests that upregulation of 
tRFs might be indirectly linked with the suppression of 
apoptosis in cancer cells.
Our discovery cohort included patient-derived PCa 
samples with different clinico-pathological characteristics. 
The major difference in tRF expression (at least 110 unique 
differentially expressed tRFs) was observed between NAP 
and PCa tissue indicating that global upregulation of tRF 
production is associated with malignant transformation. 
Interestingly, 5e-tRFs were the predominant class 
upregulated in PCa. Recently, 5’-tRFs were found to 
induce translational inhibition in siRNA-independent way 
[36]. It was shown that the repressing activity of 5’-derived 
Figure 4: qPCR validation of tRF-544, tRF-315, and tRF-562. A-C. RNA expression of tRF-544 (A), tRF-315 (B), and tRF-562 
(C) in cohorts of clinical samples obtained from Erasmus MC (cohort 1) and Tampere University Hospital (cohort 2). Mean values are 
indicated by a red line. D. Ratio of tRF-315 (derived from tRNALysCTT) to tRF-544 (derived from tRNAPheGAA). E. Progression-free survival 
curves of cohort 1 and cohort 2 based on the tRF-315/tRF544 ratio. Legend: NAP, normal adjacent prostate; PCa, prostate cancer; PCa 
cur (PCa cured), patients with no disease recurrence after radical prostatectomy; PCa recur (PCa recurrent), patients with biochemical 
recurrence or metastatic progression after radical prostatectomy; Gl <7, Gleason score <7; Gl ≥7, Gleason score 7, 8 or 9; pT2, pathological 
stage 2; pT3, pathological stage 3; *P-value ≤0.05; **P-value ≤0.01; ***P-value ≤0.001.
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tRFs was dependent on the presence of a conserved “GG” 
dinucleotide at their 3’-end, which is a common feature of 
~75% of the upregulated 5e-tRFs described in this study.
Comparing our data set with an external tRF data set 
of PCa cell lines generated by Lee et al. [5] demonstrated 
that all tRFs originating from 3’-pre-tRNA trailers and 32 
out of 36 5’-tRFs described by Lee et al. were detected 
in our study. This suggests that tRFs in prostate (cancer) 
tissue and cell lines are common and discrete biological 
entities produced by defined molecular mechanisms. For 
3’-derived tRFs we found a small overlap of only 6 out of 
77 tRFs. A possible reason for that could be that 3’-derived 
tRFs represent a class of tRFs with a less stable expression. 
On the other hand, our results demonstrate that most of 
the downregulated tRFs are 3e-tRFs, which might be a 
general feature of PCa and PCa cell lines. If that is the case, 
the limited overlap of 3’-derived tRFs between both data 
sets might be caused by the less reliable detection of low 
expressed transcripts. Downregulation of 3’-derived tRFs 
might be an important event in the onset of cancer [21]. 
Possible functional implications of 3’-tRF down regulation 
in PCa can be derived from the demonstrated involvement 
of the 3′-derived tRF CU1276 in B-cell lymphoma cells, 
which suppresses proliferation and modulates the response 
to DNA damage [21]. Another recent study in breast 
cancer described several tRFs with tumor suppressor 
function that originate from tRNAGlyTCC, tRNAGluYTC, 
tRNAAspGTC, and tRNATyrGTA [15]. Upon induction in breast 
cancer cells, these tRFs suppress the stability of multiple 
oncogenic transcripts by sequence specific displacement 
of their 3′-UTRs from the RNA-binding protein YBX1. It 
can be assumed that downregulation of such tRFs would 
lead to cancer progression. Interestingly, some of the 
down-regulated 3’-tRFs (e.g. tRF-562 and tRF-542) in our 
sequencing libraries originate from the same tRNAs. Future 
investigations should address the functional implications 
on gene regulation in PCa caused by downregulation of 
3’-derived tRFs and in particular tRF-544.
Due to high conservation of tRNAs we were 
unable to identify specific sequences that would serve 
as a recognition site of tRNA nucleases that discriminate 
and preferably cleave particular tRNAs. Recently, it was 
proposed that certain tRNAs switch from canonical to 
alternative folding and the ability to do so might cause 
the specific upregulation of their tRFs. For example, 
besides the canonical cloverleaf structure, tRNAIle has 
the potential to form a long hairpin [37]. tRNAAsp also 
adopts an alternative folding in order to bind to the Alu 
element insertion in the 3’-UTR of the mRNA of its 
own aminoacyl-tRNA synthetase [38]. Since nucleotide 
modifications are known to affect hybridization, it is 
tempting to speculate to what extend they affect the 
alternative folding of tRNAs [39].
Finally, q-PCR analysis of tRFs differentially 
expressed in different grade PCa demonstrated that the 
expression ratio tRF-544, derived from tRNAPheGAA and tRF-
315 derived from tRNALysCTT effectively discriminates high 
from low grade prostate tumors and cured from recurrent 
disease. This establishes tRFs as novel candidate biomarkers 
for the early detection of recurrent aggressive PCa.
In conclusion, our study provides a comprehensive 
catalogue of tRFs expressed in various stages of PCa and 
provides leads for the further investigation of biological 
role and marker potential of these novel RNA entities in 
prostate cancer.
MATERIALS AND METHODS
Sample cohorts and processing
The discovery set used in this study consists of 10 
sequencing libraries generated as previously described 
[24]. Briefly, each library was constructed from a total 
RNA pool prepared from four individual patient samples 
with similar pathological or genetic characteristics [40]. 
Different groups represent: normal adjacent prostate 
tissue (NAP), prostate tumors with Gleason score 6, 7, or 
8 (PCa6, PCa7, PCa8), metastatic lymph nodes (LN_PCa), 
all obtained by radical prostatectomy; benign prostate 
hyperplasia tissue (BPH) obtained by cystoprostatectomy; 
and castration resistant prostate tumors obtained by trans-
urethral resection of the prostate (TURP_PCa) [24]. The 
clinical parameters of each group are summarized in the 
Table 1. PCa groups with Gleason score 6 were divided 
into cured and recurrent disease groups or into groups with 
or without TMPRSS2-ERG fusion or ETV abnormalities. 
Sample material was obtained from the tissue banks of 
the Erasmus University Medical Center, Rotterdam, 
The Netherlands (Erasmus MC, Rotterdam, The 
Netherlands) and Tampere University Hospital (TAUH, 
Tampere, Finland). Collection and use of patient material 
was performed according to the national legislations 
concerning ethical requirements and approved by the 
Erasmus MC Medical Ethics Committee according to the 
Medical Research Involving Human Subjects Act (MEC-
2004- 261), and the Ethical Committee of the Tampere 
University Hospital. Samples were snap frozen and stored 
in liquid nitrogen. Gleason score and the percentage 
of normal and cancer epithelial cells were evaluated 
from histological sections by two pathologists. Only 
samples with more than 70% of tumor cells were used 
for sequencing library preparation. All samples that were 
used for the normal prostate pool contained 0% of tumor 
cells. Total RNA was extracted using RNABee reagent 
(Campro Scientific, GmbH, Berlin, Germany) according 
to the manufacturer’s protocol.
qPCR validation was performed in two 
separate cohorts. Clinical parameters are provided in 
Supplementary Tables 6-7). The first cohort (cohort 1) 
consists of 65 samples obtained from Erasmus MC. 
The samples were collected, handled and evaluated as 
mentioned in the previous paragraph. The second cohort 
(cohort 2) consists of 104 hormonally untreated primary 
prostate tumors from radical prostatectomy specimens 
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obtained from Tampere University Hospital. The samples 
were confirmed to contain a minimum of 70% cancerous 
or hyperplastic cells by hematoxylin/eosin staining. 
Histological evaluation and Gleason grading for the 
second set were performed by a pathologist based on 
hematoxylin/eosin stained slides. Follow-up data was 
available for 74 of these samples. The use of clinical 
material was approved by the ethical committee of the 
Tampere University Hospital. Written informed consent 
was obtained from the subjects donating the samples. 
TRI-reagent (Molecular Research Center Inc., Cincinnati, 
OH, USA) was used to collect total RNA from the freshly 
frozen clinical samples, according to the manufacturer’s 
instructions.
RNA sequencing and expression analysis
RNA pools were outsourced for library construction 
and sequencing to BGI (Beijing Genomics Institute, 
Beijing, China). Shortly, total RNA samples were size-
separated on denaturing polyacrylamide gel. RNA in the 
size range of 15-35 nt was recovered from the gel and used 
for the preparation of sequencing libraries. The libraries 
were sequenced by Illumina deep sequencing. The tRNA 
database used to map the reads was constructed from 
GtRNAdb: Genomic tRNA Database (http://gtrnadb.
ucsc.edu/) as previously described [23, 24]. Shortly, 
tRNA genes with identical sequences were merged into 
single entries. Intronic sequences provided by GtRNAdb 
were removed, to allow mapping of tRFs derived from 
mature, spliced tRNAs. Genomic tRNAs in the database 
were modified by extending the 3’-ends with a single 
“CCA” sequence. Sequencing reads were mapped to 
tRNA database using CLC-Bio Genomics Workbench 
(Aarhus, Denmark). Subsequently, tRFs were predicted 
using the FlaiMapper program and our tRF database was 
constructed [23]. The final read counts used for expression 
analysis were generated by mapping the sequencing reads 
to the tRF database. tRFs derived from 5’-pre-tRNA 
leaders (5’U-tRFs) and 3’-pre-tRNA trailers (3’U-tRFs) 
were identified by mapping the sequencing reads to a 
tRNA reference database in which the genomic sequence 
of each tRNA gene was extended by 50 bp on both sides. 
The length, position and type of tRF were calculated from 
the sum of the read counts of the following groups: NAP, 
PCa6_cur, PCa6_nofusion, PCa6_TERG, PCa6_recur, 
PCa7_recur, PCa8_recur, TURP_PCa, and LN_PCa. 
To identify differentially expressed tRFs, read counts 
were normalized as “parts per million” and Kal’s Z-test 
on proportions followed by Bonferroni correction was 
subsequently performed. The generated adjusted p-values 
lower than 0.05 were considered significant.
Quantitative real-time PCR and statistics
Total RNA extracted from clinical samples was 
reverse transcribed using miRCURY Universal cDNA 
Synthesis kit (Exiqon, Vedbaek, Denmark), by adding 
a poly-A tail to the RNA template and then reverse 
transcribing the template to cDNA using poly-T primer 
with a 3’ degenerate anchor and a 5’ universal tag. The 
provided UniSp6 spike-in RNA was added to the reverse 
transcription reaction to control for the efficiency of the 
reaction. Template amplification was performed using 
miRCURY LNA™ SYBR® Green Master Mix (Exiqon, 
Vedbaek, Denmark). Briefly, the cDNA template is 
amplified using tRF-specific custom LNA™ primers 
(Exiqon, Vedbaek, Denmark) with a forward primer 
spanning a large 5’ portion of the template and a reverse 
primer spanning the 5’ universal tag, the poly-T stretch 
and several templated nucleotides from the 3’end of the 
template. Primer pairs were designed to be specific for 
the tRF. Primer specificity was monitored by performing 
melting curve analysis and comparing its profile and 
obtained melting temperature with the melting temperature 
indicated for each amplicon. The names of tRFs, their 
sequences and custom primer set design IDs (Exiqon 
Vedbaek, Denmark) are given in Table 2. Quantitative 
real-time PCR (qPCR) was performed on an Applied 
Biosystems ABI 7900 thermocycler (Applied Biosystems, 
Waltham, Massachusetts, USA) for the cohort 1 and on 
Bio-Rad CFX96 Real Time System (Bio-Rad Laboratories, 
Hercules, California, USA) for the cohort 2. Data were 
analyzed using the ΔΔCT method and the expression of 
each tRF was normalized against the small nucleolar RNA 
SNORD38B (Reference gene primer set 2039, Exiqon, 
Vedbaek, Denmark). Statistical significance of qPCR 
expression data was assessed using Mann-Whitney U 
Table 2: tRFs selected for validation by qPCR
tRF ID tRNA isotype Anticodon Sequence 5’- 3’ Custom primer set 
Design ID
tRF-544 Phe GAA TCCCTGGTTCGATCCCGGGTTTCGGCA 205919-1
tRF-159 Arg CCT ATGGATAAGGCATTGGCCT 205895-1
tRF-368 Arg TCT GGCTCCGTGGCGCAATGGA 205891-1
tRF-562 Gly TCC TCGATTCCCGGCCAACGC 205924-1
tRF-542 Glu CTC TCCCTGGTGGTCTAGTGGTTAG 205899-1
tRF-315 Lys CTT CCCGGCTAGCTCAGTCGGTAGAGCATGG 36855-1
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test. The log-rank test was used to compare progression-
free survival distributions of the tumor samples. P-values 
lower than 0.05 were considered statistically significant. 
Statistical analysis was performed using GraphPad Prism 
version 6.0g for Mac OS X (GraphPad Software, La Jolla 
California USA, www.graphpad.com”).
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